Accès ouvert
2023
article
OpenAlex
Christopher James Fowler, Erik Stoops, Eugeen Vanmechelen, Jeroen Vanbrabant et autres
Abstract Background Synaptic disfunction is a feature of Alzheimer’s disease. Recent studies show both pre‐ and post‐synaptic termini proteins change in concentration in the CSF across the A/T/N framework. Here we investigate BACE1, neurogranin (Ng) and alpha‐synuclein, along with total‐tau (t‐tau) and …
au, be
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Julie Goossens, Alba Cervantes González, Nele Dewit, Laia Lidón et autres
Abstract Background Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membrane protein 2 (VAMP-2) has emerged as a promising biomarker of AD-related …
be, es
(code pays fourni par la source)
Accès ouvert
2023
preprint
OpenAlex
Julie Goossens, Alba Cervantes González, Nele Dewit, Laia Lidón et autres
Abstract Background: Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membrane protein 2 (VAMP-2) has emerged as a promising biomarker of AD-related …
es, be
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Shreyasee Das, Julie Goossens, Dirk Jacobs, Nele Dewit et autres
BACKGROUND: Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disease evolution or treatment responses in patients. Here, we have studied the relationship between …
nl, be
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Eugeen Vanmechelen, Nele Dewit, Jeroen Vanbrabant, Kimberley Mauroo et autres
Abstract Background Technological advancements have made it possible to translate changes in cerebrospinal fluid (CSF) into promising plasma biomarkers, such as the amyloid β ratio (Aβ42/Aβ40) and phosphorylated tau (p‐tau), but comparing CSF and plasma levels were often based on different technologies. …
be, se
(code pays fourni par la source)
2022
article
OpenAlex
Christopher James Fowler, Erik Stoops, Stephanie R. Rainey‐Smith, Eugeen Vanmechelen et autres
Abstract Background Plasma biomarkers now show an accuracy in detecting Amyloid Beta (Aβ) similar to AD biomarkers derived from cerebral spinal fluid (CSF). However, the ability of plasma AD biomarkers, alone or in combination, to predict cognitive decline has not yet been …
au, be
(code pays fourni par la source)
2022
article
OpenAlex
Shreyasee Das, Nele Dewit, Kaj Blennow, Henrik Zetterberg et autres
Abstract Background Neurofilament light chain (Nf‐L) is an established biomarker for axonal degeneration, and it is well documented that Nf‐L shows an age‐ dependent increase in plasma. Currently, all highly sensitive immunoassay formats to quantify Nf‐L in plasma are based on one …
be, se
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Kirsten E. J. Wesenhagen, Betty Marije Tijms, Lynn Boonkamp, Patty L. Hoede et autres
BACKGROUND: We previously identified four Alzheimer's disease (AD) subgroups with increasingly higher cerebrospinal fluid (CSF) levels of tau phosphorylated at threonine 181 (p-tau). These subgroups included individuals across the cognitive spectrum, suggesting p-tau subgroups could reflect distinct biological changes in AD, rather …
nl, be, se
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Shreyasee Das, Nele Dewit, Dirk Jacobs, Yolande A.L. Pijnenburg et autres
Neurofilament light chain (Nf-L) is a well-known biomarker for axonal damage; however, the corresponding circulating Nf-L analyte in cerebrospinal fluid (CSF) is poorly characterized. We therefore isolated new monoclonal antibodies against synthetic peptides, and these monoclonals were characterized for their specificity on …
be, nl, gb, fr
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Przemysław Radosław Kac, Fernando González‐Ortiz, Joel Simrén, Nele Dewit et autres
Abstract Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer’s disease (AD) biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) plasma is limited. Firstly, we assessed the diagnostic potential of p-tau231 and p-tau181 in paired plasma and serum samples. Secondly, …
se, be, gb, us
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Shreyasee Das, Nele Dewit, Dirk Jacobs, Yolande A.L. Pijnenburg et autres
Neurofilament light chain (Nf-L) is a well-known biomarker for axonal damage, however the corresponding circulating Nf-L analyte in CSF is poorly characterized. We, therefore, isolated new monoclonal antibodies against synthetic peptides, and these monoclonals were characterized for their specificity on brain-specific intermediate …
be, nl, gb, fr
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Christopher James Fowler, Erik Stoops, Stephanie R. Rainey‐Smith, Eugeen Vanmechelen et autres
ABSTRACT Background In Alzheimer’s disease, plasma Aβ 1-42 and p-tau predict high amyloid status from Aβ-PET, however the extent to which combination of both plasma assays predict remains unknown. Methods Prototype Simoa assays were used to measure plasma samples from cognitively normal …
au, be
(code pays fourni par la source)